PMID- 10629555
OWN - NLM
STAT- MEDLINE
DCOM- 20000214
LR  - 20151119
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 189
IP  - 4
DP  - 1999 Dec
TI  - Survival of patients with HTLV-I-associated lymph node lesions.
PG  - 539-45
AB  - Adult T-cell leukaemia/lymphoma (ATLL), is a malignant condition associated with 
      human T-cell leukaemia virus type I (HTLV-I). Usually, although not uniformly, 
      histopathological examination of the lymph nodes shows a pleomorphic type. In 
      addition, some patients with pre-overt ATLL show a Hodgkin's disease-like 
      morphology and lymph nodes in non-neoplastic carriers show features of 
      lymphadenitis. To characterize further the clinicopathological features of 
      HTLV-I-associated lymphadenopathy, the histopathological features of the lymph 
      nodes of 289 patients were classified into five types: lymphadenitis ( n=14), 
      Hodgkin's-like (Hodgkin's) ( n=18), pleomorphic (medium and large cells) ( 
      n=219), pleomorphic small cell ( n=11), and anaplastic large cell (ALC) ( n=27). 
      Survival data were analysed according to the histopathological features of the 
      lymph nodes. The pleomorphic type, which showed typical features of ATLL, was 
      associated with a highly aggressive course and an initially high mortality, 
      followed by a rapid decrease in survival. This pattern was also observed in 
      patients with the ALC type. All cases with lymphadenitis were still alive at the 
      end of the study, while survival progressively decreased in the Hodgkin's type. 
      The small cell type showed an initial rapid decrease in survival followed by a 
      plateau. These results show that the survival trends of patients with pleomorphic 
      and anaplastic lymph node lesions are similar to those with ATL lymphoma, while 
      patients with the lymphadenitis type of lesion were considered to have a 
      non-neoplatic status. There is at present no effective therapy for ATLL, but in 
      the future, these classification and survival data might be useful for the 
      selection of appropriate chemotherapeutic regimens for patients with ATLL.
CI  - Copyright 1999 John Wiley & Sons, Ltd.
FAU - Ohshima, K
AU  - Ohshima K
AD  - Department of Pathology, School of Medicine, Fukuoka University, Fukuoka, Japan.
FAU - Suzumiya, J
AU  - Suzumiya J
FAU - Sato, K
AU  - Sato K
FAU - Kanda, M
AU  - Kanda M
FAU - Simazaki, T
AU  - Simazaki T
FAU - Kawasaki, C
AU  - Kawasaki C
FAU - Haraoka, S
AU  - Haraoka S
FAU - Kikuchi, M
AU  - Kikuchi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma/mortality/pathology
MH  - Cyclophosphamide/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Hodgkin Disease/mortality/pathology
MH  - Humans
MH  - Leukemia-Lymphoma, Adult T-Cell/drug therapy/*mortality/*pathology
MH  - Lipoma/mortality/pathology
MH  - Lymph Nodes/*pathology
MH  - Lymphadenitis/pathology
MH  - Prednisone/therapeutic use
MH  - Survival Analysis
MH  - Survival Rate
MH  - Vincristine/therapeutic use
EDAT- 2000/01/12 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/01/12 09:00
PHST- 2000/01/12 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/01/12 09:00 [entrez]
AID - 10.1002/(SICI)1096-9896(199912)189:4<539::AID-PATH465>3.0.CO;2-T [pii]
AID - 10.1002/(SICI)1096-9896(199912)189:4<539::AID-PATH465>3.0.CO;2-T [doi]
PST - ppublish
SO  - J Pathol. 1999 Dec;189(4):539-45. doi: 
      10.1002/(SICI)1096-9896(199912)189:4<539::AID-PATH465>3.0.CO;2-T.